BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 1462825)

  • 1. Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
    Jones TH; Figueroa CD; Smith CM; Bhoola KD
    Agents Actions Suppl; 1992; 38 ( Pt 2)():175-82. PubMed ID: 1462825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
    Jones TH; Figueroa CD; Smith CM; Cullen DR; Bhoola KD
    J Endocrinol; 1992 Jul; 134(1):149-54. PubMed ID: 1500840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
    Ma W; Ikeda H; Yoshimoto T
    Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
    Schatz H; Stracke H; Hildebrandt G
    Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
    De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
    Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
    Hamester U; Saeger W; Lüdecke DK
    Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging of tumours of the sellar region. Evaluation of treatment with bromocriptine retard.
    Lundberg PO; Bergström K; Thuomas KA; Muhr C; Enoksson P
    Acta Radiol Suppl; 1986; 369():310-3. PubMed ID: 2980483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical treatment of prolactin-secreting pituitary adenomas. Influence of the size of the adenoma].
    Kuhn JM; Gancel A; Weinstein A; Courtois H; Schrub JC; Tadie M; Wolf LM
    Presse Med; 1985 Mar; 14(9):525-8. PubMed ID: 3157164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine.
    Yin D; Kondo S; Takeuchi J; Morimura T
    Oncol Res; 1993; 5(9):383-7. PubMed ID: 8038459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor effect of bromocriptine in 5 cases of invasive prolactinoma].
    Guibout M; Jaquet P; Grisoli F; Tapias PL; Mouly A
    Ann Med Interne (Paris); 1982; 133(1):48-50. PubMed ID: 7065589
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas.
    Nishioka H; Haraoka J; Akada K
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):768-72. PubMed ID: 14974920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of hormone secretion in GH-secreting pituitary adenomas by receptor-subtype specific somatostatin analogues in vitro.
    Cap J; Marekova M; Cerman J; Malirova E; Suba P; Netuka D; Hana V; Marek J
    Gen Physiol Biophys; 2003 Jun; 22(2):201-12. PubMed ID: 14661732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
    Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
    J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study.
    Tindall GT; Kovacs K; Horvath E; Thorner MO
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1178-83. PubMed ID: 6752167
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland.
    Esiri MM; Bevan JS; Burke CW; Adams CB
    J Clin Endocrinol Metab; 1986 Aug; 63(2):383-8. PubMed ID: 3722328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors.
    Lamberts SW; de Quijada M; Klijn JG
    J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome.
    Hubbard JL; Scheithauer BW; Abboud CF; Laws ER
    J Neurosurg; 1987 Dec; 67(6):816-21. PubMed ID: 3681421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assay.
    Thodou E; Kontogeorgos G; Kyrodimou E; Salla H; Ramyar L; Vamvassakis E; Piaditis G; Anagnostopoulos N; Tzanis S; Levedis A; Rologis D; Asa SL
    J Endocrinol Invest; 1999 Oct; 22(9):671-80. PubMed ID: 10595830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.